Cargando…

Tumor-derived exosomes induce PD1(+) macrophage population in human gastric cancer that promotes disease progression

Macrophages constitute a major component of tumor-infiltrating immune cells. M2 macrophages have been reported to promote tumor progression through promoting tumor angiogenesis and metastasis and regulating T-cell function. Here, we identified a protumorigenic subset of macrophages that constitutive...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Furong, Li, Bin, Wei, Yucai, Zhao, Yang, Wang, Li, Zhang, Peng, Yang, Jinwei, He, Wenting, Chen, Hao, Jiao, Zuoyi, Li, Yumin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968036/
https://www.ncbi.nlm.nih.gov/pubmed/29799520
http://dx.doi.org/10.1038/s41389-018-0049-3
Descripción
Sumario:Macrophages constitute a major component of tumor-infiltrating immune cells. M2 macrophages have been reported to promote tumor progression through promoting tumor angiogenesis and metastasis and regulating T-cell function. Here, we identified a protumorigenic subset of macrophages that constitutively expressed programmed cell death 1 (PD1) and accumulated in advanced-stage gastric cancer (GC). These PD1(+) tumor-associated macrophages (TAMs) exhibited an M2-like surface profile, with a significant increase in the expression of CD206, IL-10, and CCL1, and a clear decrease in the expression of MHC class II, CD64, and IL-12 and the ability to phagocytose ovalbumin. Moreover, PD1(+) TAMs can suppress CD8(+) T-cell function and this immunosuppressive activity can effectively be enhanced upon triggering PD1 signal. GC-derived exosomes effectively educated monocytes to differentiate into PD1(+) TAMs with M2 phenotypic and functional characteristics. Together, our results are the first to show that GC-derived exosomes can effectively induce PD1(+) TAM generation, and these cells can produce a large number of IL-10, impair CD8(+) T-cell function, and thereby create conditions that promote GC progression. Thus, methods in which immunotherapy is combined with targeting PD1(+) TAMs and tumor-derived exosomes should be used to restore immune function in GC patients.